RAFAGEN’s primary focus is the development and commercialization of next generation gene expression systems with applications in solving the most challenging problems in molecular therapeutics. RAFAGEN will leverage its core technology to build up a strategic framework for revenue generation in licensing deals and service contracts, and eventually, for its own development of highly effective molecular therapy drugs.

In the field of recombinant protein and monoclonal antibody therapeutics, RAFAGEN’s technology will facilitate a marked increase in drug production from manufacturing facilities. Protein drugs will be launched in the market and revenue will be generated at a faster rate than ever before. In this rapidly emerging and highly competitive market, companies applying RAFAGEN’s state-of-art technologies will amass unparalleled selective advantages.

In gene therapy drug development, RAFAGEN’s Targeting Promoters will allow unprecedented levels of efficiency and precision in targeted gene expression. In cancer gene therapy, Targeting Promoters will help kill cancer cells with the highest possible efficiencies while leaving normal cells unharmed. RAFAGEN’s Targeting Promoter technology will allow a rapid construction of gene therapy drug pipelines. RAFAGEN seeks to further cultivate the field of gene therapy by increasing the safety and efficiency of gene/cell therapy drugs and treatment of cancer and other diseases